PIPELINE

TBI Therapy and Neurodegenerative Diseases Therapy

We successfully completed proof of concept for the drug development of TBI therapy, neurodegenerative diseases therapy and attenuation of irradiation-induced neuronal damage. The efficacy of the gene therapy has been tested in both mouse models of traumatic brain injury (TBI) and irradiation-induced neuronal damage, demonstrating significant effectiveness. The invention has been protected by a patent, which has been issued. We are currently preparing for the IND (Investigational New Drug) submission.

Cancer Therapy

The concepts of developing multiple comprehensive novel drugs, specializing in minimizing toxicity, maximizing efficacy and overcoming drug resistance for the treatment of solid tumors and hematological malignancies, have been finalized. These concepts span RNA-based therapy, large molecules, immunotherapy, molecular biology, cell therapy, and protein engineering. We are currently in the process of conducting preclinical studies in preparation for the IND submission. 

Innovative gene expression regulation-based immunotherapy, gene therapy and small molecule for broad-spectrum cancers therapy are currently Patent Pending in the USA.

Drugs Aimed at Enhancing Organ Transplantation Survival, and Autoimmune Diseases Therapy

The development concepts for a novel drug aimed at improving organ transplantation survival, and autoimmune diseases therapy have been finalized and are set to progress to the Research and Development stage. These encompass areas such as immunomodulation, immune tolerance induction, and gene manipulation. 

Innovative gene expression regulation-based immunomodulation aimed at autoimmune diseases therapy and immunosuppression for organ transplantation are  currently patent pending in the USA.